Karyopharm Therapeutics (KPTI) Receivables - Net (2019 - 2025)
Karyopharm Therapeutics (KPTI) has disclosed Receivables - Net for 7 consecutive years, with $26.2 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Receivables - Net fell 14.91% year-over-year to $26.2 million, compared with a TTM value of $26.2 million through Dec 2025, down 14.91%, and an annual FY2025 reading of $26.2 million, down 14.91% over the prior year.
- Receivables - Net was $26.2 million for Q4 2025 at Karyopharm Therapeutics, down from $31.9 million in the prior quarter.
- Across five years, Receivables - Net topped out at $47.1 million in Q4 2022 and bottomed at $17.8 million in Q1 2021.
- Average Receivables - Net over 5 years is $29.5 million, with a median of $30.9 million recorded in 2024.
- The sharpest move saw Receivables - Net soared 109.3% in 2022, then plummeted 42.74% in 2023.
- Year by year, Receivables - Net stood at $22.5 million in 2021, then skyrocketed by 109.3% to $47.1 million in 2022, then tumbled by 42.74% to $27.0 million in 2023, then grew by 14.11% to $30.8 million in 2024, then decreased by 14.91% to $26.2 million in 2025.
- Business Quant data shows Receivables - Net for KPTI at $26.2 million in Q4 2025, $31.9 million in Q3 2025, and $32.9 million in Q2 2025.